57.77

0.16% -0.075

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $57.77, with a volume of 151.36K. It is down -0.16% in the last 24 hours and down -12.30% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$57.85

Open:

$56.89

24h Volume:

151.36K

Relative Volume:

0.07

Market Cap:

$9.03B

Revenue:

$1.22B

Net Income/Loss:

$77.95M

P/E Ratio:

118.10

EPS:

0.4892

Net Cash Flow:

$224.06M

1W Performance:

-0.28%

1M Performance:

-12.30%

6M Performance:

+6.16%

1Y Performance:

-7.14%

1-Day Range:

$56.25

$57.99

1-Week Range:

$54.59

$59.06

52-Week Range:

$46.01

$72.16

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

612-379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2024-10-30

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	57.72	9.05B	1.22B	77.95M	224.06M	0.4892
VRTX Vertex Pharmaceuticals Inc	470.32	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	767.10	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	735.42	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	326.74	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	294.65	33.09B	5.36B	287.73M	924.18M	2.5229

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-25	Upgrade	Citigroup	Neutral → Buy
Jul-22-25	Resumed	Stephens	Overweight
Jul-09-25	Initiated	TD Cowen	Buy
May-30-25	Initiated	Wells Fargo	Overweight
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

Mar 04, 2026

TECH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 04, 2026

TD Asset Management Inc Acquires 36,424 Shares of Bio-Techne Corp $TECH - MarketBeat

Mar 04, 2026

Cresset Asset Management Boosts Stake in Bio-Techne - National Today

Mar 04, 2026

Cresset Asset Management LLC Increases Position in Bio-Techne Corp $TECH - MarketBeat

Mar 04, 2026

Mar 03, 2026

Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch

Mar 03, 2026

Bio-Techne at TD Cowen Conference: Strategic Growth and Challenges - Investing.com

Mar 03, 2026

TECH Technical Analysis & ETF Price Forecast - Intellectia AI

Mar 03, 2026

Segall Bryant & Hamill LLC Sells 34,680 Shares of Bio-Techne Corp $TECH - MarketBeat

Mar 03, 2026

Champlain Investment Partners LLC Sells 963,441 Shares of Bio-Techne Corp $TECH - MarketBeat

Mar 03, 2026

American Century Companies Inc. Boosts Bio-Techne Stake - National Today

Mar 03, 2026

American Century Companies Inc. Grows Stock Position in Bio-Techne Corp $TECH - MarketBeat

Mar 03, 2026

3 Reasons to Avoid TECH and 1 Stock to Buy Instead - Finviz

Mar 03, 2026

Citigroup Trims Stake in Bio-Techne Corp - National Today

Mar 03, 2026

Mar 02, 2026

Bio-Techne Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Mar 02, 2026

Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch

Mar 02, 2026

Royce & Associates Cuts Stake in Bio-Techne Corp - National Today

Mar 02, 2026